Gut bacterial chemical linked to lower thinking scores in adults
An observational study of 1,196 adults without cognitive impairment linked higher blood imidazole propionate to lower thinking-test scores and Alzheimer’s-related biological markers.
Our read
Mechanisms- Studied:
- Cohort study of 1,196 cognitively unimpaired adults
- What changed:
- Higher plasma ImP levels were associated with lower preclinical cognitive scores
- The catch:
- ImP was measured by untargeted metabolomics with arbitrary values, not absolute concentrations
- Stake:
- An author founded Implexion Pharma and two hold shares in it. An author founded Roxbiosens and holds shares in it.
- In the record:
- One of 4 papers on imidazole propionate on record: 2 with results in people.
Editor of record: Boris Djordjevic · AgingResearch.News
Among 1,196 adults without cognitive impairment, whose average age was 61.2 years, researchers measured blood imidazole propionate, a chemical made by gut bacteria, in an observational study. Higher levels were associated with lower cognitive scores and biological markers of Alzheimer’s disease and related dementias. Participants in the highest quarter of blood levels had lower initial cognitive scores and steeper age-related declines than those in the lowest quarter.
A Mendelian randomization analysis, which used inherited DNA differences, also linked genetically predicted higher levels to greater Alzheimer’s risk. In separate experiments, sustained imidazole propionate dosing worsened Alzheimer’s-like changes in male mice. Tests in human brain blood-vessel cells grown in the lab found that the chemical weakened the cells’ barrier function.
Why it matters
For Alzheimer’s disease and related dementias, the authors suggest that targeting this gut bacterial chemical may offer a strategy to modify risk.
Caveats
The human analyses did not test whether lowering the chemical would change cognition or Alzheimer’s risk. All 1,196 adults lacked cognitive impairment, and people with a parental history of Alzheimer’s dementia were overrepresented in one contributing cohort.
From the paper
- Result
Consistent with this notion, data from the most recent and largest GWAS meta-analysis for AD revealed that the T allele of rs7969761 was directionally consistently associated with increased risk of AD dementia (OR = 1.02; 95% CI 1.01-1.04; P = 2.8 × 10⁻³).
Results, Genetically increased plasma ImP levels are associated with increased AD risk
- Limitation
Our human cohort consisted primarily of cognitively unimpaired individuals, which may limit the generalizability of our findings to broader or more diverse populations, including those with varying degrees of cognitive impairment or differing geographic and demographic backgrounds.
Quoted word for word from the full text on PubMed Central.
- Imidazole propionate
- GSK3B
- Microbiome composition
- Alzheimer's disease
- Alzheimer's disease and related dementias
- Mice
The paper
Gut bacterial metabolite imidazole propionate potentiates Alzheimer's disease pathology
University of Wisconsin–Madison
Nature Communications, Jun 26, 2026, Open access
Comments
Be the first to comment.